ENZ vs. PSNL, XGN, DMTK, PMD, BDSX, NSPR, CKPT, PRE, NOTV, and EUDA
Should you be buying Enzo Biochem stock or one of its competitors? The main competitors of Enzo Biochem include Personalis (PSNL), Exagen (XGN), DermTech (DMTK), Psychemedics (PMD), Biodesix (BDSX), InspireMD (NSPR), Checkpoint Therapeutics (CKPT), Prenetics Global (PRE), Inotiv (NOTV), and EUDA Health (EUDA). These companies are all part of the "medical" sector.
Personalis (NASDAQ:PSNL) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.
Personalis currently has a consensus price target of $5.00, suggesting a potential upside of 242.47%. Given Enzo Biochem's higher possible upside, equities research analysts clearly believe Personalis is more favorable than Enzo Biochem.
Enzo Biochem received 102 more outperform votes than Personalis when rated by MarketBeat users. However, 65.48% of users gave Personalis an outperform vote while only 56.53% of users gave Enzo Biochem an outperform vote.
Personalis has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, Enzo Biochem has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
Enzo Biochem has a net margin of 99.28% compared to Enzo Biochem's net margin of -124.89%. Personalis' return on equity of -36.71% beat Enzo Biochem's return on equity.
In the previous week, Personalis had 2 more articles in the media than Enzo Biochem. MarketBeat recorded 3 mentions for Personalis and 1 mentions for Enzo Biochem. Enzo Biochem's average media sentiment score of 0.76 beat Personalis' score of 0.00 indicating that Personalis is being referred to more favorably in the media.
61.9% of Personalis shares are owned by institutional investors. Comparatively, 36.9% of Enzo Biochem shares are owned by institutional investors. 4.1% of Personalis shares are owned by company insiders. Comparatively, 15.5% of Enzo Biochem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Enzo Biochem has lower revenue, but higher earnings than Personalis.
Summary
Personalis beats Enzo Biochem on 8 of the 15 factors compared between the two stocks.
Get Enzo Biochem News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enzo Biochem Competitors List
Related Companies and Tools
